Nutriband Inc. sells 90% of Pocono Pharmaceutical to Earthvision Bio for $5M, retaining 10% ownership post-acquisition.
Quiver AI Summary
Nutraband Inc. has announced an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million, with the transaction expected to close on December 31, 2025. EarthVision Bio is focused on developing sustainable product alternatives to plastics and other materials, leveraging the expertise of its founders, Dr. Gordon Moore and Dr. Hans Franke. Following the acquisition, Nutriband's shareholders will retain a 10% stake in EarthVision Bio. The proceeds from the sale will be used to further develop Nutriband's AVERSA Fentanyl, an innovative abuse-deterrent opioid patch that aims to reduce misuse and accidental exposure, potentially generating significant annual sales.
Potential Positives
- Earthvision Bio, founded by notable figures Dr. Gordon Moore and Dr. Hans Franke, represents a strategic alignment with experienced leadership in sustainable product development.
- Nutriband Inc. retains a 10% shareholding in Earthvision Bio following the sale, allowing for potential future benefits from the subsidiary's growth and success.
- The $5M proceeds from the sale of Pocono Pharmaceutical will support the development of AVERSA Fentanyl, which has the potential for significant annual sales of $80 million to $200 million.
- AVERSA Fentanyl is a unique product aimed at addressing the pressing issue of opioid abuse, enhancing Nutriband's market position in the pharmaceutical sector.
Potential Negatives
- The sale of a 90% interest in its subsidiary Pocono Pharmaceutical for only $5M could be viewed as an undervaluation of its assets, raising questions about Nutriband Inc.'s financial health.
- Shareholders retaining only 10% of the shareholding in Earth Vision Bio following the acquisition may diminish their influence and potential benefits from future growth.
- The dependency on future financing and regulatory approvals for the development and marketing of its lead product, AVERSA Fentanyl, introduces significant uncertainty about the company’s prospects.
FAQ
What is the focus of Earthvision Bio's product development?
Earthvision Bio focuses on developing sustainable alternatives to plastic, molded fiber, wood, and paper products.
Who are the founders behind Earthvision Bio?
Earthvision Bio was founded by Dr. Gordon Moore, founder of Intel, and Dr. Hans Franke, former chairman of Chevron Europe.
What percentage of shareholding do Nutriband shareholders retain post-acquisition?
Nutriband shareholders will retain 10% of their shareholding in Earthvision Bio after the acquisition is completed.
When is the expected closing date for the transaction?
The expected closing date for the transaction is December 31, 2025.
What technology does Nutriband's AVERSA product incorporate?
Nutriband's AVERSA product incorporates abuse-deterrent technology aimed at preventing misuse of transdermal patches.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NTRB Hedge Fund Activity
We have seen 9 institutional investors add shares of $NTRB stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG added 19,636 shares (+1963600.0%) to their portfolio in Q3 2025, for an estimated $138,433
- CETERA INVESTMENT ADVISERS added 18,900 shares (+inf%) to their portfolio in Q3 2025, for an estimated $133,245
- CONSOLIDATED PORTFOLIO REVIEW CORP removed 10,350 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $72,967
- US BANCORP \DE\ removed 4,798 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $33,825
- GEODE CAPITAL MANAGEMENT, LLC removed 3,688 shares (-5.8%) from their portfolio in Q3 2025, for an estimated $26,000
- VANGUARD GROUP INC added 3,111 shares (+1.6%) to their portfolio in Q3 2025, for an estimated $21,932
- NORTHERN TRUST CORP added 2,463 shares (+21.5%) to their portfolio in Q3 2025, for an estimated $17,364
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Earthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke, ex-chairman for Chevron Europe
Nutriband Inc. Shareholders will retain 10% of the shareholding in Earth Vision Bio following the acquisition
The expected closing date for the transaction is Dec 31, 2025.
ORLANDO, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that it has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio.
Earthvision Bio has developed and are commercializing a new category of sustainable products created by Dr. Gordon Moore, the founder of Intel (NASDAQ: INTC), and Dr. Hans Franke, who was board chairman for Chevron Europe. The Company has developed a sustainable way to replace plastic, molded fiber, wood, and paper products with Earth-friendly alternatives.
Nutriband Inc. Shareholders will retain 10% of the shareholding in Earth Vision Bio following the acquisition.
Nutriband inc. will use the proceeds from the sale of Pocono Pharma towards its continued development of AVERSA Fentanyl which has the potential to be the world's first and only abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach annual US sales of $80 million to $200 million.
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, including opioids and stimulant drugs, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com . Any material contained in or derived from
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's periodic and current reports on Form 10-K, Forms 10-Q and 8-K and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information :
Nutriband Inc.
Phone: 407-377-6695
Email:
[email protected]
Earthvision Bio
Tina Hoefer
Phone: 213-531-9995
Email:
[email protected]
SOURCE: Nutriband Inc.
